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Abstract Increasing evidence has indicated that dysregula-
tion of long non-coding RNAs (lncRNAs) can contribute to
the progression and metastasis of human cancer, including
HCC. Previous studies have shown that the lncRNA
AFAP1-AS1 plays a critical role in cancer. However, the roles
of AFAP1-AS1 in HCC remain to be determined. In the pres-
ent study, AFAP1-AS1 was found to be increased in HCC
tissues, and high AFAP1-AS1 expression was associated with
tumor size, TNM stage, vascular invasion, and poor progno-
sis. Silencing of AFAP1-AS1 significantly reduced cell pro-
liferation, clonal growth, cell migration, and invasion and in-
creased apoptosis in vitro. Furthermore, AFAP1-AS1 silenc-
ing markedly reduced tumor growth in a murine allograft
model in vivo. The results suggested that AFAP1-AS1 is im-
portant in HCC development and serves as a therapeutic target
of HCC.
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Introduction
Hepatocellular carcinoma (HCC) is the sixth most com-
mon diagnosed cancer and the third leading cause of
cancer death in the world [1, 2]. Although advances in
treatment have been made in HCC in the past decades,
surgical resection and liver transplantation are the prima-
ry effective approaches to treat HCC, and the overall
5-year survival rate of HCC patients remains very poor
due to its advanced tumor stages at the time of diagnosis
[3, 4]. Increasing evidence has shown that several genet-
ic or epigenetic alterations contribute to tumorigenesis,
and unrestricted cell growth and invasion are the most
two key traits of HCC [5–7]. However, limited informa-
tion is available regarding how to improve the probabil-
ity of survival. Therefore, a better understanding of the
mechanisms of key genes that can be used to provide
novel therapeutic strategies is urgently needed for pa-
tients with HCC.
Emerging evidence has suggested that non-coding
RNAs (ncRNAs) play an essential role in various physio-
logical and pathological processes, including cell prolifer-
ation, differentiation, apoptosis, invasion, metabolism, de-
velopmental timing, and immune responses [8]. lncRNAs,
functional RNA molecules larger than 200 nucleotides in
length have been shown to exert their functions as onco-
genes or tumor suppressors, and their aberrant expression
contributes to carcinogenesis [9–11]. For example,
lncRNA GAS5 has been shown to be significantly down-
regulated in HCC tissues, and the overexpression of GAS5
suppresses HCC cell migration and invasion through neg-
atively regulating the expression of miR-21 [12]. lncRNA
HOTAIR has been reported to be upregulated in breast
cancer, pancreatic cancer, non-small cell lung cancer, and
Xu Lu, Chuang Zhou and Renfeng Li contributed equally to this work.
* Shuijun Zhang
zhangshuijun66@126.com
1 Department of Hepatobiliary and Pancreatic Surgery, the First
Affiliated Hospital of Zhengzhou University, Jianshe East Road No.
1, Zhengzhou, Henan 450052, China
2 Key Laboratory of Hepatobiliary and Pancreatic Surgery and
Digestive Organ Transplantation of Henan Province, Jianshe East
Road No. 1, Zhengzhou, Henan 450052, China
Tumor Biol. (2016) 37:9699–9707
DOI 10.1007/s13277-016-4858-8
gastric cancer, and high HOTAIR expression is associated
with poor prognosis [13–16].
Previous studies have shown that AFAP1-AS1 is up-
regulated in esophageal adenocarcinoma, pancreatic duc-
tal adenocarcinoma, lung cancer, and nasopharyngeal car-
cinoma, and high AFAP1-AS1 expression is associated
with lymph node metastasis, perineural invasion, and poor
survival [17–20]. However, little is known concerning the
potential role of AFAP1-AS1 in the development and pro-
gression of HCC. In the current study, we detected the
expression of AFAP1-AS1 in HCC and found that
AFAP1-AS1 was dramatically increased in HCC tissues
compared with matched normal tissues. High AFAP1-
AS1 expression was correlated with poor clinicopatholog-
ical features and poor outcome in HCC patients. Further
functional studies of AFAP1-AS1 suggested that knock-
down of AFAP1-AS1 could decrease cell proliferation in
vitro and in vivo.
Materials and methods
Patients and tissue specimens
HCC tissues and normal tissues were obtained from 156 pa-
tients who had undergone surgical resection of HCC between
April 2008 and February 2011 at The First Affiliated Hospital
of Zhengzhou University, China. No chemotherapy or radio-
therapy treatment had been administered to these patients pri-
or to surgery. All collected specimens were immediately fro-
zen in liquid nitrogen and stored at −80 °C until RNA extrac-
tion. Tumors and noncancerous tissues were confirmed using
histological diagnoses by two experienced pathologists.
Written informed consent was obtained from the patients,
and this study was approved by the research ethics committee
of The First Affiliated Hospital of Zhengzhou University.
Cell lines and cell culture
Non-malignant liver cells (LO2), the human embryonic kidney
cell line 293 T, and human hepatoma cell lines (SMMC-7721,
Bel-7402, MHCC-97 L, andMHCC-97H) were obtained from
Shanghai Cell Bank of the Chinese Academy of Sciences
(Shanghai, China). All of the cells were maintained in
Dulbecco’s modified Eagle’s medium (DMEM; Hyclone,
Logan, UT, USA) supplemented with 10 % fetal bovine serum
(Invitrogen, Grand Island, NY, USA) and 1 % penicillin G and
streptomycin in 37 °C humidified air containing 5 % CO2.
RNA isolation and quantitative real-time polymerase
chain reaction (qRT-PCR)
Total RNA was isolated from tissues and cells using Trizol
Reagent (Invitrogen) according to the manufacturer’s proto-
col. RNA concentration and integrity were determined using
the NanoDrop2000 spectrophotometer (Thermo Fisher
Scientific, Waltham, MA, USA) and standard RNA gel elec-
trophoresis. Real-time PCR was performed using
SYBR®Green (TaKaRa, Dalian, China) and the ABI Prism
7900 Sequence Detection System (Applied Biosystems,
Foster City, CA, USA) according to the manufacturer’s pro-
tocol. The primers used were as follows: AFAP1-AS1, for-
ward 5′-TCGCTCAATGGAGTGACGGCA-3′ and reverse
5′-CGGCTGAGACCGCTGAGAACTT-3′; GAPDH, for-
ward 5′- CACCCACTCCTCCACCTTTG-3′ and reverse 5′-
CCACCACCCTGTTGCTGTAG-3′. The fold-change for
AFAP1-AS1 was normalized to GAPDH.
Lentiviral infection
Lentivirus-mediated suppression of humanAFAP1-AS1was con-
structed as previously described [19]. Lentivirus packaging and
cell transduction were carried out as previously described [21].
Fig. 1 AFAP1-AS1 expression is increased in human HCC tissues and
cell lines. a The relative expression of AFAP1-AS1 was detected in 156
pairs of primary HCC tissues and their corresponding adjacent tissues. b
qRT-PCR analysis was performed to assess the AFAP1-AS1 levels in
HCC cells (SMMC-7721, BEL-7402, MHCC-97 L, and MHCC-97H)
and LO2. *P< 0.05 and **P< 0.01
9700 Tumor Biol. (2016) 37:9699–9707
Immunohistochemical staining
Standard immunohistochemical procedures were performed
using anti-Ki67 polyclonal antibody (ab66155; Abcam) as
previously described [21].
Cell proliferation and clone formation assay
For the cell proliferation assay, 2 × 103 cells in 100 μL of
complete culture were seeded in 96-well culture plates with
five replicate wells. Next, 10 μL of CCK-8 (Dojindo,
Kumamoto, Japan) was added to each well at 24, 48, 72,
and 96 h and incubated at 37 °C for another 2 h. The absor-
bance was measured at 450 nm using a Multiskan® Spectrum
system (Thermo Fisher Scientific).
For the clone formation assay, 600 cells were plated into
6-well plates and were maintained in media containing 10 %
FBS with the medium being replaced every 3 days. Colonies
were fixed with methanol and stained with 0.1 % crystal violet
2 weeks later. The visible colonies were photographed and
manually counted.
Apoptosis assay
Flow cytometry was performed to determine the apoptotic
rate. Cells were harvested and washed three times with
phosphate-buffered saline. Staining with Annexin V-PE
and Propidium iodide (PI) was performed using the PE
annexin V apoptosis detection kit (BD Pharmingen, San
Diego, CA, USA) according to the manufacturer’s recom-
mendations, and the cells were then analyzed using a
Cytomics FC-500 flow cytometer (Beckman Coulter,
Inc., Fullerton, CA, USA).
Wound healing assay
Cells were plated onto in 6-well plates and cultured to 80 %
confluence. Wounds were created with a sterilized pipette tip,
and the detached cells were washed off thrice with PBS.
Images were taken at 0 and 36 h after the scratching using
digital microscopy.
Cell migration and invasion assays
Cell migration and invasion were performed as we have pre-
viously described [21]. Briefly, 5 × 104 MHCC-97 L or
MHCC-97H cells transduced with si-AFAP1-AS1 or the re-
spective control were added to the upper chamber of an insert
coated with or without Matrigel (BD Biosciences, San Jose,
CA, USA). Cell migration was allowed to proceed at 37 °C for
24 h, and cell invasion was allowed to occur at 37 °C for 48 h.
After removing the cells on the inner surface of the filter
membrane with a sterile cotton swab, cells were stained with
0.1 % crystal violet, imaged, and counted using digital
microscopy.
Western blotting
Western blot assays were performed as we previously de-
scribed [21]. The membranes were incubated with
anti-BCL-2 antibody (#2876), anti-Bax antibody (#2772),
anti-MMP-9 antibody (#3852), and anti-GAPDH antibody
(#2118), all from CST (Cell Signaling Technology, Danvers,
MA, USA), and subsequently, with the appropriate
Table 1 Correlation between AFAP1-SA1 expression and the
clinicopathological features in HCC patients
Variables AFAP1-SA1
expression level
Low High P value
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ALT alanine aminotransferase, TNM tumor-node-metastasis,
a Fisher’s exact tests and Χ2 tests for all other analyses
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horseradish peroxidase-conjugated secondary antibody
(Beyotime, Zhejiang, China).
Tumorigenicity in nude mice
The animal experiments were approved by the Committee on
the Ethics of Animal Experiments of Zhengzhou University.
This study was performed in accordance with the recommen-
dations in the Guide for the Care and Use of Laboratory
Animals of the National Institutes of Health. MHCC-97H
cells (1 × 107 cells) transduced with the negative control
(Scramble) or siAFAP1-AS1 were injected into the flanks of
4-week-old nude mice. The tumor size was measured using
hand calipers every week. All of the mice were sacrificed
5 weeks after inoculation. The tumor tissues were removed
from each mouse, weighed, imaged, embedded in 10 % par-
affin, and subjected to IHC staining.
Statistical analysis
Statistical analyses were performed using SPSS 17.0 software
(SPSS Inc., Chicago, IL, USA). All of the data were expressed
as the means±SD (standard deviation), and Student’s t test
was used to analyze the differences between two groups.
The correlation between AFAP1-AS1 expression and clinico-
pathological features was evaluated using Pearson χ2 test.
The Kaplan-Meier method was performed to evaluate the sur-
vival rate in patients with HCC. A P value less than 0.05 was
regarded as statistically significant.
Results
AFAP1-AS1 is significantly increased in HCC samples
and HCC cell lines
AFAP1-AS1 expression levels in 156 HCC tissue samples and
156 matched normal liver tissue samples were examined by
quantitative real-time PCR. AFAP1-AS1 levels in cancer
samples were significantly higher than those in the noncancer-
ous samples (P<0.001; Fig. 1a). Furthermore, qRT-PCR was
performed to detect the expression of AFAP1-AS1 in diverse
HCC cell lines and a non-malignant liver cell line. As shown
in Fig. 1b, the AFAP1-AS1 expression level was significantly
increased in HCC cell lines compared with a non-malignant
liver cell line (LO2). These results suggested that AFAP1-AS1
might function as an oncogene in HCC.
Association between AFAP1-AS1 expression
and clinicopathological features in HCC
To understand the significance of AFAP1-AS1 overexpres-
sion in HCC, we explored the associations between AFAP1-
AS1 expression and the patients’ clinicopathological features
(Table 1). There was a significant association between
AFAP1-AS1 expression and tumor size (P=0.012), vascular
invasion (P=0.035), and TNM stage (P=0.01). However,
AFAP1-AS1 expression was not associated with other param-
eters such as age, gender, or liver cirrhosis in HCC patients.
Furthermore, according to the median AFAP1-AS1 expres-
sion in tumor tissues, the patients were classified into the high
AFAP1-AS1 expression group (n = 78) or relative low
AFAP1-AS1 expression group (n= 78). The patients with
lower AFAP1-AS1 expression had better overall survival
(OS) and disease-free survival (DFS) (Fig. 2a, b). These re-
sults indicated that AFAP1-AS1 might be a potential prognos-
tic biomarker for HCC patients.
Knockdown of AFAP1-AS1 inhibits HCC cell
proliferation in vitro
To explore the biological significance of AFAP1-AS in
HCC, we transfected lentivirus-mediated siRNA into
MHCC-97 L and MHCC-97H cells, which had high en-
dogenous AFAP1-AS levels. As shown in Fig. 3a, the
expression of AFAP1-AS was significantly decreased
compared with that of the negative control (SCR). Cell
proliferation assays were performed to investigate the
Fig. 2 Kaplan-Meier analysis of
HCC survival rates in relation to
AFAP1-AS1 expression. The
overall survival a and disease-free
survival b rates of HCC patients
with high (n= 78) and low
(n = 78) levels of AFAP1-AS1
expression. The P values were
determined using the log-rank test
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effect of AFAP1-AS on cell viability using the CCK-8
assay. Our resu l t s showed tha t knockdown of
AFAP1-AS expression significantly suppressed cell
growth in MHCC-97 L and MHCC-97H cells compared
with that in the respective controls (Fig. 3b). Furthermore,
colony formation assays showed that downregulation of
Fig. 3 Knockdown of AFAP1-AS1 decreases HCC cell proliferation
in vitro. a qRT-PCR was performed to detect the expression of AFAP1-
AS1 in MHCC-97 L and MHCC-97H cells transduced with SCR or
siAFAP1-AS1. The effects of knockdown of AFAP1-AS1 in cells on
cell proliferation b colony formation c and apoptosis d were examined.
*P< 0.05 and **P< 0.01
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AFAP1-AS could significantly inhibit colony formation in
MHCC-97 L and MHCC-97H cells (Fig. 3c). In addition,
AFAP1-AS silencing induced an increase in the apoptosis
levels using the Annexin V Apoptosis Assay (Fig. 3d).
These data suggest that AFAP1-AS plays a critical role
in HCC cell proliferation in vitro.
Knockdown of AFAP1-AS1 inhibits HCC cell migration
and invasion
Unrestricted cell growth and motility are the two most
important traits of cancers. Thus, wound healing assay
and transwell assays were performed to evaluate the cell
Fig. 4 The effects of AFAP1-
AS1 knockdown on cell invasion.
a Representative images of
wound-healing assay showed that
the migration ability of MHCC-
97 L and MHCC-97H cells
transduced with SCR or
siAFAP1-AS1 at 0 h and 48 h
time point, respectively. b The
Boyden chamber assay was
employed to examine the
invasion ability of MHCC-97 L
and MHCC-97H cells transduced
with SCR or siAFAP1-AS1,
respectively. c The expression of
Ki-67, BCL-2, Bax, and MMP-9
in MHCC-97 L and MHCC-97H
cells transduced with SCR or
siAFAP1-AS1 was determined by
western blotting. **P< 0.01
9704 Tumor Biol. (2016) 37:9699–9707
motility capability. As determined by the wound healing
assay, knockdown of AFAP1-AS1 markedly inhibited the
migratory ability of the MHCC-97 L and MHCC-97H
cells (Fig. 4a). The transwell assay also showed that
motility was significantly decreased in cells transduced
with siAFAP1-AS1 compared with that in the negative
control (Fig. 4b). To explore whether AFAP1-AS1 exerts
its functions through the proliferation- and apoptosis-
related genes that are known to be involved in cancer,
we examined the expression of Ki67, Bcl-2, Bax, and
MMP9. As shown in Fig. 4c, knockdown of AFAP1-
AS1 resulted in a dramatic decrease in Ki67, Bcl-2,
and MMP9 levels and an increase in Bax levels. Taken
together, the data strongly suggest that AFAP1-AS1 pro-
motes HCC cell proliferation and invasion through me-
diating proliferation- and apoptosis-related gene expres-
sion in vitro.
Knockdown of AFAP1-AS1 suppresses tumor growth
in vivo
To further determine whether AFAP1-AS1 silencing affects
tumorigenesis, MHCC-97H cells transduced with SCR or
siAFAP1-AS1 were subcutaneously inoculated into nude
mice. All of the mice were sacrificed 5 weeks after injection,
and tumors derived from the AFAP1-AS1-silencing group
developed more slowly than those from the SCR group
(Fig. 5a). Consistent with tumor size, the average tumor
weight in the siAFAP1-AS1 group was significantly lower
than that in the SCR group (Fig. 5b). Tumor growth in the
knockdown AFAP1-AS1 group was slower than that in the
SCR group (Fig. 5c). Furthermore, qRT-PCR was performed
to detect the expression of AFAP1-AS1 in the xenograft tumor
tissues. Our results showed that the levels of AFAP1-AS1
expression in tumor tissues formed in the siAFAP1-AS1
Fig. 5 AFAP1-AS1 silencing
inhibited tumor growth in a
xenograft mouse model. a
Representative photographs of
tumors are shown. Tumor weight
b and tumor growth curves c in
mice are shown for MHCC-97H
cells transduced with SCR or
siAFAP1-AS1. d qRT-PCR was
used to detect the average
expression of AFAP1-AS1 in
xenograft tumors. e
Representative images of IHC
staining showed the expression of
Ki67 in xenograft tumor tissues
from the siAFAP1-AS1 group or
SCR group. **P< 0.01
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group were lower than those of the tumors formed in the SCR
group (Fig. 5d). In addition, immunostaining revealed that the
tumors derived from the siAFAP1-AS1 group showed weaker
Ki-67 expression than that in tumors from the SCR group
(Fig. 5e). These data further supported the role of AFAP1-
AS1 in HCC cell growth in vivo.
Discussion
Accumulating evidence has shown that lncRNAs are associ-
ated with many functions in various aspects of cell biology,
and increasing attention has been paid to their roles in tumors
[9–11]. Previous studies have demonstrated that AFAP1-AS1,
localized in the antisense DNA strand of the AFAP1 gene,
regulates the invasion and metastasis of lung cancer and
PDAC cells [18, 19]. Recently, Hao et al. provided evidence
that AFAP1-AS1 mediated cell malignant behavior by affect-
ing the expression of several small GTPase family members
and molecules in the actin cytokeratin signaling pathway in
nasopharyngeal carcinoma [20]. However, the expression and
functions of AFAP1-AS1 in HCC remain unclear. In the cur-
rent study, we provided the first evidence that AFAP1-AS1
was significantly upregulated in HCC tissues compared with
that in adjacent normal tissues, and high AFAP1-AS1 expres-
sion in HCC patients was associated with an increased tumor
size, vascular invasion, advanced TNM stage, and poor prog-
nosis, findings that were consistent with those in previous
studies. These findings suggested that AFAP1-AS1 acts as
an oncogene in the progression of HCC.
Because high AFAP1-AS1 expression was associated with
tumor size in HCC, we surmised that AFAP1-AS1 might play
a key role in tumor cell proliferation. To further elucidate the
functions of AFAP1-AS1 in HCC, we knocked down
AFAP1-AS1 in MHCC-97 L and MHCC-97H with high en-
dogenous AFAP1-AS1 expression using RNAi-mediated sup-
pression. Our results showed that AFAP1-AS1 knockdown
could significantly inhibit HCC cell proliferation and invasion
in vitro. In addition, flow cytometric analysis indicated the
inhibitory effect of AFAP1-AS1 silencing on the proliferation
of HCC cells by inducing apoptosis. Similarly, the gain- and
loss-of-function strategies for AFAP1-AS1 expression result-
ed in changes in cell proliferation and apoptosis in esophageal
cancer [17] and migration and invasion in pancreatic cancer
and nasopharyngeal carcinoma [19, 20]. It is well known that
aberrant BCL-2 and Bax expression is involved in cancer [22].
As we expected, AFAP1-AS1 silencing led to a decrease in
Ki-67, BCL-2, and MMP-9 and an increase in Bax. In addi-
tion, AFAP1-AS1 knockdown significantly inhibited tumor
growth in vivo, confirming the vitro experiments.
In conclusion, our results showed that AFAP1-AS1 is re-
markably upregulated in HCC tissues and is significantly cor-
related with the malignancy status and poor prognosis.
Furthermore, AFAP1-AS1 silencing suppressed cell prolifer-
ation and induced cell apoptosis at least partly through regu-
lating proliferation- and apoptosis-related genes. However,
dysregulation of AFAP1-AS1 is only the tip of iceberg; more
studies on the functions of AFAP1-AS1 in HCC are needed.
Acknowledgments This study was supported by the National Natural
Science Foundation of China (grant no. 81171849) and Zhengzhou Inno-
vation Team Project (Grant No. 131PCXTD617).
Compliance with ethical standards
Conflicts of interest None
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted
use, distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a link
to the Creative Commons license, and indicate if changes were made.
References
1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A.
Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.
2. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiolo-
gy and molecular carcinogenesis. Gastroenterology. 2007;132:
2557–76.
3. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet.
2012;379:1245–55.
4. Arzumanyan A, Reis HM, Feitelson MA. Pathogenic mechanisms
in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev
Cancer. 2013;13:123–35.
5. Poon RT. Prevention of recurrence after resection of hepatocellular
carcinoma: a daunting challenge. Hepatology. 2011;54:757–9.
6. Dong QZ, Zhang XF, Zhao Y, Jia HL, Zhou HJ, Dai C, et al.
Osteopontin promoter polymorphisms at locus −443 significantly
affect the metastasis and prognosis of human hepatocellular carci-
noma. Hepatology. 2013;57:1024–34.
7. Wang B, Fang J, Qu L, Cao Z, Zhou J, Deng B. Upregulated TRIO
expression correlates with a malignant phenotype in human hepa-
tocellular carcinoma. Tumour Biol. 2015.
8. Ulitsky I, Bartel DP. LincRNAs: genomics, evolution, and mecha-
nisms. Cell. 2013;154:26–46.
9. Guo X, Xia J, Deng K. Long non-coding RNAs: emerging players
in gastric cancer. Tumour Biol. 2014;35:10591–600.
10. He Y, Meng XM, Huang C, Wu BM, Zhang L, Lv XW, et al. Long
noncoding RNAs: novel insights into hepatocelluar carcinoma.
Cancer Lett. 2014;344:20–7.
11. Batista PJ, Chang HY. Long noncoding RNAs: cellular address
codes in development and disease. Cell. 2013;152:1298–307.
12. Hu L, Ye H, Huang G, Luo F, Liu Y, Liu Y, et al. Long noncoding
RNA GAS5 suppresses the migration and invasion of hepatocellu-
lar carcinoma cells via miR-21. Tumour Biol. 2015.
13. Kim K, Jutooru I, Chadalapaka G, Johnson G, Frank J, Burghardt R,
et al. HOTAIR is a negative prognostic factor and exhibits pro-
oncogenic activity in pancreatic cancer. Oncogene. 2013;32:1616–25.
14. Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ,
et al. Long non-coding RNA HOTAIR reprograms chromatin state
to promote cancer metastasis. Nature. 2010;464:1071–6.
9706 Tumor Biol. (2016) 37:9699–9707
15. Liu XH, Liu ZL, Sun M, Liu J, Wang ZX, De W. The long non-
coding RNA HOTAIR indicates a poor prognosis and promotes
metastasis in non-small cell lung cancer. BMCCancer. 2013;13:464.
16. ZhaoW, Dong S, Duan B, Chen P, Shi L, Gao H, et al. HOTAIR is a
predictive and prognostic biomarker for patients with ad-
vanced gastric adenocarcinoma receiving fluorouracil and plat-
inum combination chemotherapy. Am J Transl Res. 2015;7:
1295–302.
17. Wu W, Bhagat TD, Yang X, Song JH, Cheng Y, Agarwal R, et al.
Hypomethylation of noncoding DNA regions and overexpression of
the long noncoding RNA, AFAP1-AS1, in Barrett’s esophagus and
esophageal adenocarcinoma. Gastroenterology. 2013;144:956–66.
18. Zeng Z, Bo H, Gong Z, Lian Y, Li X, Li X, et al. AFAP1-AS1, a
long noncoding RNA upregulated in lung cancer and promotes
invasion and metastasis. Tumour Biol. 2015.
19. Ye Y, Chen J, Zhou Y, Fu Z, Zhou Q, Wang Y, et al. High expres-
sion of AFAP1-AS1 is associated with poor survival and short-term
recurrence in pancreatic ductal adenocarcinoma. J Transl Med.
2015;13:137.
20. Bo H, Gong Z, Zhang W, Li X, Zeng Y, Liao Q, et al. Upregulated
long non-coding RNA AFAP1-AS1 expression is associated with
progression and poor prognosis of nasopharyngeal carcinoma.
Oncotarget. 2015;6:20404–18.
21. Yang X, Zhang XF, Lu X, Jia HL, Liang L, Dong QZ, et al.
MicroRNA-26a suppresses angiogenesis in human hepatocellular
carcinoma by targeting hepatocyte growth factor-cMet pathway.
Hepatology. 2014;59:1874–85.
22. Khan M, Maryam A, Qazi JI, Ma T. Targeting apoptosis and mul-
tiple signaling pathways with icariside II in cancer cells. Int J Biol
Sci. 2015;11:1100–12.
Tumor Biol. (2016) 37:9699–9707 9707
